Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Natera Inc (NTRA)

Natera Inc (NTRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,081,164
  • Shares Outstanding, K 141,731
  • Annual Sales, $ 2,306 M
  • Annual Income, $ -208,160 K
  • EBIT $ -287 M
  • EBITDA $ -191 M
  • 60-Month Beta 1.65
  • Price/Sales 12.12
  • Price/Cash Flow N/A
  • Price/Book 15.92

Options Overview Details

View History
  • Implied Volatility 50.94% (+1.29%)
  • Historical Volatility 42.91%
  • IV Percentile 59%
  • IV Rank 33.76%
  • IV High 86.29% on 04/08/25
  • IV Low 32.92% on 06/16/25
  • Expected Move (DTE 12) 13.94 (7.04%)
  • Put/Call Vol Ratio 0.45
  • Today's Volume 152
  • Volume Avg (30-Day) 939
  • Put/Call OI Ratio 1.14
  • Today's Open Interest 21,610
  • Open Int (30-Day) 17,428
  • Expected Range 184.19 to 212.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.55
  • Number of Estimates 5
  • High Estimate -0.41
  • Low Estimate -0.65
  • Prior Year -0.50
  • Growth Rate Est. (year over year) -10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
192.60 +2.87%
on 03/03/26
220.65 -10.21%
on 02/18/26
-4.91 (-2.42%)
since 02/06/26
3-Month
192.60 +2.87%
on 03/03/26
256.36 -22.71%
on 01/07/26
-46.42 (-18.98%)
since 12/05/25
52-Week
125.38 +58.02%
on 04/07/25
256.36 -22.71%
on 01/07/26
+56.63 (+40.02%)
since 03/06/25

Most Recent Stories

More News
Natera (NTRA) Stock Trades Up, Here Is Why

Natera (NTRA) Stock Trades Up, Here Is Why

NTRA : 198.13 (+0.50%)
Why Natera (NTRA) Shares Are Falling Today

Why Natera (NTRA) Shares Are Falling Today

NTRA : 198.13 (+0.50%)
Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

11 scientific abstracts, including 4 oral presentations and a concurrent publication in Nature Medicine, underscore how Signatera MRD can improve quality of life for patients with genitourinary cancers...

NTRA : 198.13 (+0.50%)
Natera: Q4 Earnings Snapshot

Natera: Q4 Earnings Snapshot

NTRA : 198.13 (+0.50%)
Natera Reports Fourth Quarter and Full Year 2025 Financial Results

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the fourth quarter and full year ended December 31, 2025. ...

NTRA : 198.13 (+0.50%)
Natera Earnings: What To Look For From NTRA

Natera Earnings: What To Look For From NTRA

NTRA : 198.13 (+0.50%)
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

Interventional trial validates adaptive Signatera-guided treatment approach, achieving strong 63% response rate while reducing chemotherapy exposure in 74% of patients ...

NTRA : 198.13 (+0.50%)
Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2025, after the market...

NTRA : 198.13 (+0.50%)
Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

Large prospective study to evaluate a non-invasive prenatal screening test

NTRA : 198.13 (+0.50%)
Natera Submits Signatera™ CDx PMA to FDA

Application backed by landmark phase 3 data validating MRD-guided treatment in bladder cancer

NTRA : 198.13 (+0.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California.

See More

Key Turning Points

3rd Resistance Point 204.96
2nd Resistance Point 201.65
1st Resistance Point 199.89
Last Price 198.13
1st Support Level 194.82
2nd Support Level 191.51
3rd Support Level 189.75

See More

52-Week High 256.36
Fibonacci 61.8% 206.33
Last Price 198.13
Fibonacci 50% 190.87
Fibonacci 38.2% 175.41
52-Week Low 125.38

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar